Epirubicin hydrochloride is a semisynthetic L-arabino derivative of doxorubicin that inhibits Topoisomerase, DNA/RNA synthesis, and Foxp3, reducing regulatory T cell activity. A stereoisomer of doxorubicin, it undergoes β-glucuronidation, mitigating dose-limiting side effects. It is cytotoxic to HeLa cells (ID50 = 9 μM) and has shown efficacy alone or in combination therapies across various cancers, including breast, ovarian, lymphoma, pancreatic, gastric, and colorectal cancers. Reagent grade, for research use only.
Usually ships within 24 hours.